DOCUMENT RESOURCES FOR EVERYONE
Documents tagged
A phase I study of CHR-2797, an orally active aminopeptidase inhibitor, in elderly and/or treatment refractory patients with acute myeloid leukemia or.
Documents A phase I study of CHR-2797, an orally active aminopeptidase inhibitor, in elderly and/or treatment....

Slide 1A phase I study of CHR-2797, an orally active aminopeptidase inhibitor, in elderly and/or treatment refractory patients with acute myeloid leukemia or multiple myeloma…

Derivation and Validation of a Prediction Tool for Venous Thromboembolism (VTE): A VERITY Registry Study Roopen Arya, Shankaranarayana Paneesha, Aidan.
Documents Derivation and Validation of a Prediction Tool for Venous Thromboembolism (VTE): A VERITY Registry.....

Slide 1 Derivation and Validation of a Prediction Tool for Venous Thromboembolism (VTE): A VERITY Registry Study Roopen Arya, Shankaranarayana Paneesha, Aidan McManus, Nick…

The Medicare Oncology Care Model – What It Is and What It Means for Practice April 9, 2015.
Documents The Medicare Oncology Care Model – What It Is and What It Means for Practice April 9, 2015.

Slide 1 The Medicare Oncology Care Model – What It Is and What It Means for Practice April 9, 2015 Slide 2 Moderator: Steve Allen, MD Professor of Medicine, Hofstra North…

Spring 2006 Version 3.0 Overview Module. FTA/ESF Overview Module Introduction to the Session Welcome to the FTA/ESF Overview Training Session 1.1.
Documents Spring 2006 Version 3.0 Overview Module. FTA/ESF Overview Module Introduction to the Session Welcome...

Slide 1 Spring 2006 Version 3.0 Overview Module Slide 2 FTA/ESF Overview Module Introduction to the Session Welcome to the FTA/ESF Overview Training Session 1.1 Slide 3 FTA/ESF…

Evaluating the Performance of a Previously Reported Risk Score to Predict Venous Thromboembolism: A VERITY Registry Study Denise O'Shaughnessy, Peter Rose,
Documents Evaluating the Performance of a Previously Reported Risk Score to Predict Venous Thromboembolism: A....

Slide 1 Evaluating the Performance of a Previously Reported Risk Score to Predict Venous Thromboembolism: A VERITY Registry Study Denise O'Shaughnessy, Peter Rose, Fran…

LATEST CONCEPTS IN LARGE CELL AND HODGKIN LYMPHOMAS Morton Coleman, M.D. Director, Center for Lymphoma and Myeloma New York-Presbyterian Hospital Weill.
Documents LATEST CONCEPTS IN LARGE CELL AND HODGKIN LYMPHOMAS Morton Coleman, M.D. Director, Center for...

LATEST CONCEPTS IN LARGE CELL AND HODGKIN LYMPHOMAS Morton Coleman, M.D. Director, Center for Lymphoma and Myeloma New York-Presbyterian Hospital Weill Cornell Medical Center…

John H. Alexander, MD, MHS on behalf of the APPRAISE-2 Investigators Apixaban with Antiplatelet Therapy After Acute Coronary Syndrome: Results of the APPRAISE-2.
Documents John H. Alexander, MD, MHS on behalf of the APPRAISE-2 Investigators Apixaban with Antiplatelet...

John H. Alexander, MD, MHS on behalf of the APPRAISE-2 Investigators Apixaban with Antiplatelet Therapy After Acute Coronary Syndrome: Results of the APPRAISE-2 Trial Sponsored…

People want care. Where it comes from is secondary Breda Flood EFA President breda.flood@efanet.org Athens, 24th May 2014 1.
Documents People want care. Where it comes from is secondary Breda Flood EFA President [email protected]....

Slide 1People want care. Where it comes from is secondary Breda Flood EFA President [email protected] Athens, 24th May 2014 1 Slide 2 Disclosures for Breda Flood In…

RARE GERMLINE VARIABILITY IN PEDIATRIC LEUKEMIA. Cancer Biology Series January 29, 2013 Todd Druley, MD, PhD Assistant Professor of Pediatric and Genetics.
Documents RARE GERMLINE VARIABILITY IN PEDIATRIC LEUKEMIA. Cancer Biology Series January 29, 2013 Todd Druley,...

RARE GERMLINE VARIABILITY IN PEDIATRIC LEUKEMIA. Cancer Biology Series January 29, 2013 Todd Druley, MD, PhD Assistant Professor of Pediatric and Genetics Presenter Disclosure…

Popular Categories
Relevant Tags